Research Article

Correlation between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and Serum Uric Acid to Serum Creatinine Ratio

Table 1

Characteristics of study participants (n = 228).

Mild MAFLD and non-MAFLD (n = 175)Moderate-severeMAFLD (n = 53)

Male [n (%)]122 (69.7%)45 (84.9%)0.029
Female [n (%)]53 (30.3%)8 (15.1%)
Age (years)47.0 (41.0–55.0)48.0 (36.5–53.0)0.266
BMI (kg/m2)26.92 ± 3.0229.39 ± 3.74<0.001
Liver CT value50.39 ± 7.3630.63 ± 6.73<0.001
Liver/spleen CT ratio0.933 (0.847–1.078)0.609 (0.488–0.671)<0.001
ALT (mmol/L)30.0 (21.0–41.0)45.0 (34.0–69.5)<0.001
AST (mmol/L)22.0 (18.0–26.0)26.0 (21.5–35.5)<0.001
TBil (μ·mol/L)12.43 (9.20–16.78)12.180 (9.965–17.165)0.623
DBil (μ·mol/L)1.94 (1.56–2.54)2.250 (1.690–2.845)0.103
sUA (μ·mol/L)354.47 ± 79.48412.77 ± 75.12<0.001
sCr (μ·mol/L)65.80 ± 14.6269.16 ± 11.810.091
sUA/Cr5.51 ± 1.196.14 ± 1.550.008
TG (mmol/L)1.84 (1.32–2.83)2.050 (1.485–2.570)0.333
FPG (mmol/L)5.57 (5.17–6.04)5.690 (5.340–6.665)0.075
Dyslipidemia (n (%))136 (77.7%)46 (86.8%)0.149
Abnormal liver function (n (%))69 (39.4%)37 (69.8%)<0.001
Hypertension (n (%))50 (28.6%)16 (30.2%)0.820
Diabetes (n (%))10 (5.7%)5 (9.4%)0.339
Abdominal obesity (n (%))150 (85.7%)46 (86.8%)0.843
Smoking history (n (%))60 (34.3%)20 (37.7%)0.645
Drinking history (n (%))59 (33.7%)24 (45.3%)0.125

Data were expressed as mean ± standard deviation and analyzed by Student’s t-test when approximately normally distributed or otherwise expressed as median (25th–75th percentiles) and analyzed by the Mann–Whitney U test for continuous variables or expressed as number (percentage) and analyzed by chi-square test for categorical variables. MAFLD, metabolic-associated fatty liver disease; BMI, body mass index; CT, computed tomography; ALT, alanine transaminase; AST, aspartate aminotransferase; TBil, total bilirubin; DBil, direct bilirubin; sUA, serum uric acid; sCr, serum creatinine; sUA/Cr, serum uric acid to serum creatinine ratio; TG, triglyceride; TC, total cholesterol; FPG, fasting plasma glucose.